Methylprednisolone and Nephrosclerosis - a phase IV clinical study of FDA data

Summary:

Nephrosclerosis is reported as a side effect among people who take Methylprednisolone (methylprednisolone), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Aranesp, and have Anaemia.

The phase IV clinical study analyzes which people have Nephrosclerosis when taking Methylprednisolone. It is created by eHealthMe based on reports of 58,374 people who have side effects when taking Methylprednisolone from the FDA, and is updated regularly.

What is Methylprednisolone?

Methylprednisolone has active ingredients of methylprednisolone. It is often used in inflammation. eHealthMe is studying from 59,645 Methylprednisolone users. Check the latest studies of Methylprednisolone.

What is Nephrosclerosis?

Nephrosclerosis (hardening of the kidney due to renovascular disease) is found to be associated with 346 drugs and 314 conditions by eHealthMe. Check the latest studies of Nephrosclerosis.

On Jul, 19, 2026

58,374 people reported to have side effects when taking Methylprednisolone.
Among them, 13 people (0.02%) have Nephrosclerosis.

Could Methylprednisolone cause Nephrosclerosis?

Among these 13 people:

How long have people been on Methylprednisolone when they have Nephrosclerosis? *

What is the gender of people who have Nephrosclerosis when taking Methylprednisolone? *

female: 83.33 %
male: 16.67 %

What is the age of people who have Nephrosclerosis when taking Methylprednisolone? *

What are other drugs people take besides Methylprednisolone? *

What are other side effects people have besides Nephrosclerosis? *

Renal Disorder (kidney disease): 5 people, 38.46%
Blood Albumin Decreased: 4 people, 30.77%
High Blood Pressure: 4 people, 30.77%
Weight Increased: 4 people, 30.77%
Atelectasis (partial or complete collapse of the lung): 3 people, 23.08%
Gallbladder Disorder: 3 people, 23.08%
Gastritis (inflammation of stomach): 3 people, 23.08%
General Physical Health Deterioration (weak health status): 3 people, 23.08%
Granuloma (a small area of inflammation due to tissue injury): 3 people, 23.08%
Haematochezia (passage of stools containing blood): 3 people, 23.08%

What are the existing conditions these people have? *

Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands): 3 people, 23.08%
Multiple Myeloma (cancer of the plasma cells): 3 people, 23.08%
High Blood Pressure: 3 people, 23.08%
Anaemia (lack of blood): 3 people, 23.08%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 15.38%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 15.38%
Urinary Tract Infection: 1 person, 7.69%
Pain: 1 person, 7.69%
Ill-Defined Disorder: 1 person, 7.69%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Methylprednisolone and have Nephrosclerosis?

- Check whether Nephrosclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Methylprednisolone:

Methylprednisolone (59,645 reports)

Nephrosclerosis treatments and more:

Nephrosclerosis (2,137 reports)

Browse all side effects of Methylprednisolone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephrosclerosis:

Nephrosclerosis (346 drugs)

Browse all the conditions that are associated with Nephrosclerosis:

Nephrosclerosis (314 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methylprednisolone (the active ingredients of Methylprednisolone) and Methylprednisolone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.